ArticleMaterials today. Bio2025
pH-responsive 2D niobium carbide nanosheets for targeted circPUM1 siRNA delivery in ovarian cancer therapy.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Exosomal circular RNAs in the tumor immune microenvironment: From regulatory mechanisms to therapeutic opportunities and translational hurdles (Review).International journal of molecular medicine · 2026Review
- Folate-Targeted Co-Delivery of Curcumin and siRela Nanoparticles Synergistically Treat Sepsis-Associated Acute Kidney Injury.ACS omega · 2026Article
- Exosome-mediated siRNA delivery in cancer: Loading strategies, targeting approaches, and therapeutic outcomes.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Review
- Circular RNAs in tumor biology and immunology: molecular mechanisms and therapeutic implications.Molecular cancer · 2026Review
- Small Extracellular Vesicles: Unraveling Their Roles in Ovarian Cancer Progression and Tapping Into Clinical Application Potential.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer progression is closely associated with tumor microenvironment (TME) dysregulation, particularly pathological angiogenesis driven by exosome-mediated crosstalk. Here, we elucidate that ovarian cancer-derived circPUM1 promotes angiogenesis by transferring to vascular endothelial cells via exosomes. Mechanistically, circPUM1 upregulates the expression of RAB27B and VEGFA by sponging miR-607, thus boosting release of exosome facilitated by RAB27B and directly activating VEGF signaling in endothelial cells to foster angiogenesis. To disrupt this circPUM1-driven TME modulation, we engineered an innovative pH-responsive 2D niobium carbide nanosheets loaded with circPUM1 siRNA. Through excessive PEI grafting, we functionalized the nanosheets with cationic property, achieving efficient negative-charged siRNA loading. Further surface PEGylation shielded the nanosheets' positive charge, reducing off-target effect and systemic toxicity, while acidic TME triggered PEG exfoliation for tumor-specific circPUM1 siRNA delivery. Functional cellular assays and an intraperitoneal tumor-bearing mouse model validated that the nanosheet-delivered circPUM1 siRNA effectively inhibited angiogenesis and peritoneal dissemination by knocking down circPUM1 expression and subsequently downregulating its downstream targets. This study uncovers a novel exosome-mediated angiogenesis mechanism and develops innovative MXene nanosheets for pH-responsive siRNA delivery providing a promising strategy for ovarian cancer precision therapy with significant clinical translational value and application potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.